1170 infection control & hospital epidemiology october 2015, vol. 36, no. 10 In conclusion, no high quality data support the use of CP for
endemic MRSA or VRE and there may be patient harms and unintended consequences associated with CP. The burden of CP is not insignificant because approximately 25% of hospi- talized patients are on CP when surveillance culturing is employed. Although most US hospitals currently use CP for MRSA and VRE, a high proportion of SHEA Research Network respondents expressed interest in foregoing CP for the control of endemic MRSA and VRE. At least 30 US hos- pitals do not use CP for endemic MRSA or VRE and generally rely on broad-based, bundled interventions such as hand hygiene, chlorhexidine bathing, environmental cleaning, and checklists. Higher quality research on the risks and benefits of CP is needed. Until more definitive data are available, the use of CP for control of endemic MRSA or VRE in acute care hospitals should be guided by local needs and resources.
acknowledgments
We thank Valerie Deloney for her invaluable assistance with the preparation of this article. Financial support. SHEA Research Network. Potential conflicts of interest. D.J.M. reports that he has an advisory/con-
sultant role for Welch Allyn, Sanogiene/Biomed, and 3M. B.C.C. reports that he has received research grants/contracts from Pfizer, Merck, and the Centers for Disease Control and Prevention (Preventing Hemodialysis-Related Bloodstream Infections). E.P.D. reports that he has an advisory/consultant role and has received honoraria from Merck, Baxter, Ortho-McNeil, Targanta, Schering-Plough, Astellas, CareFusion, Durata, Pfizer, and Rib-X; and research grants/contracts from Exoxemis. B.L.J. reports that she has received research grants/contracts from Gilead Sciences and Pfizer Canada, education grants from GlaxoSmithKline, Sunovion Pharmaceuticals Canada, Optimer Pharmaceuticals Canada for Infectious Diseases Continuing Medical Educa- tion for Family Physicians (October 2013), and grants from Merck Canada, ViiV Healthcare Canada, Bristol-Myers Squibb Canada, and Gilead Sciences for Atlantic Canada Human Immunodeficiency Virus Educational Conference. R.M. reports that she has received research grants/contracts from Medimmune. K.V.S. reports that he has received research grants/contracts from Nanosphere, Techlab, and Premier. G.B. reports that he has received research grants from Pfizer, Cardinal Healthcare, BioVigil, and Vestagen. M.E.R. reports that he has received research grants/contracts from National Institutes of Health, 3M, Magnolia; Consultant, and Sharklet. All other authors report no conflicts of interest relevant to this article.
Address correspondence to Daniel J. Morgan, MD, MS, 685 W. Baltimore
St, MSTF 334, University of Maryland, Baltimore, MD 21201 (dmorgan@epi.
umaryland.edu).
references
1. Fätkenheuer G, Hirschel B, Harbarth S. Screening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence. Lancet 2014;385:1146–1149.
2. Morgan DJ, Kaye KS, Diekema DJ. Reconsidering isolation pre- cautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant. Enterococcus. JAMA 2015;312: 1395–1396.
3. Morgan DJ, Pineles L, Shardell M, et al. The effect of contact precautions on healthcare worker activity in acute care hospitals. Infect Control Hosp Epidemiol 2013;34:69–73.
4. Calfee DP, Salgado CD, Milstone AM, et al. Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:772–796.
5. CDC/HICPAC. Prevention of transmission of multidrug resistant organisms 2009.
www.cdc.gov/hicpac/mdro/mdro_5.html. Updated December 29, 2009. Accessed November 2014.
6. Bearman GM, Marra AR, Sessler CN, et al. A controlled trial of universal gloving versus contact precautions for preventing the transmission of multidrug-resistant organisms. Am J Infect Control 2007;35:650–655.
7. Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. Am J Infect Control 2006;34:476–483.
8. Trick WE, Weinstein RA, DeMarais PL, et al. Comparison of routine glove use and contact-isolation precautions to prevent transmission of multidrug-resistant bacteria in a long-term care facility. J Am Geriatr Soc 2004;52:2003–2009.
9. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admis- sion and nosocomial infection in surgical patients. JAMA 2008;299:1149–1157.
10. Marshall C, Richards M, McBryde E. Do active surveillance and contact precautions reduce MRSA acquisition? A prospective interrupted time series. PLOS ONE 2013;8:e58112.
11. Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial- resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014;14:31–39.
12. Huskins WC, Huckabee CM, O’Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011;364:1407–1418.
13. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006;43:971–978.
14. Lucet JC, Paoletti X, Lolom I, et al. Successful long-term program for controlling methicillin-resistant Staphylococcus aur- eus in intensive care units. Intensive Care Med 2005;31: 1051–1057.
15. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008;148:409–418.
16. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA 2013;310:1571–1580.
17. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011;364:1419–1430.
18. Fournier S, Monteil C, Lepainteur M, et al. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution, a nine-year experience, France, 2004 to 2012. Euro Surveill 2014;19. pii:20802.
19. Rossini FA, Fagnani R, Leichsenring ML, et al. Successful pre- vention of the transmission of vancomycin-resistant enterococci in a Brazilian public teaching hospital. Rev Soc Bras Med Trop 2012;45:184–188.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140